Reading RVPH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RVPH free→Reading RVPH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RVPH free→QuarterlyIQ Insights · RVPH
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard ; Transfer of Listing. As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the “Company”) was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (“Nasdaq”) and the Company had until May 11, 2026, which was the maximum extent of t…
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any…
Other Events. The Company is including the below update to its risk factors, for the purpose of supplementing and updating the “Risk Factors” disclosure contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026. The below update should be read in conjunction with the “Risk Factors” disclosure appearing in the foregoing report, as further supplemented and updated in the Company’s other fi…
of this Current Report on Form 8-K, on April 15, 2026, the Company issued a letter to shareholders announcing certain business updates, including in connection with the Company’s program for the development of brilaroxazine for the treatment of schizophrenia and regarding the Company’s intellectual property strategy. The Company announced certain efforts centered on extending the long-term value of the brilaroxzine program and preparing for the next phase of development. A component of that s…
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any…
Regulation FD Disclosure. On March 18, 2026, the Company issued a press release regarding the launch of the Offering (the “Launch Press Release”). On March 18, 2026, the Company issued a press release announcing that it had priced the Offering (the “Pricing Press Release”). Copies of the Launch Press Release and the Pricing Press Release are furnished hereto as Exhibits 99.1 and Exhibit 99.2, respectively. The information in this Current Report on Form 8-K under Item 7.01, including the infor…
Entry into a Material Definitive Agreement. Registered Public Offering On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into agreements, including a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) an aggregate of 6,283,334 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Co…
Other Events. The Company is including the below update to its risk factors, for the purpose of supplementing and updating the “Risk Factors” disclosure contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on April 3, 2025, and its Quarterly Reports on Form 10-Q for the periods ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the SEC on May 15, 2025, August 14, 2025 and November…
of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard ; Transfer of Listing. On January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for…
Other Events. The Company is including the below update to its risk factors, for the purpose of supplementing and updating the “Risk Factors” disclosure contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on April 3, 2025, and its Quarterly Reports on Form 10-Q for the periods ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the SEC on May 15, 2025, August 14, 2025 and November…
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 14, 2025, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) received a letter (the “MVLS Compliance Letter”) from the Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) formally notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities (“MVLS”) requirement for continued listing on The Nasdaq…
Entry into a Material Definitive Agreement. Registered Public Offering On September 18, 2025, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into agreements, including a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) an aggregate of 27,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share…
Regulation FD Disclosure. On September 18, 2025, the Company issued a press release regarding the launch of the Offering (the “Launch Press Release”). On September 18, 2025, the Company issued a press release announcing that it had priced the Offering (the “Pricing Press Release”). Copies of the Launch Press Release and the Pricing Press Release are furnished hereto as Exhibits 99.1 and Exhibit 99.2, respectively. The information in this Current Report on Form 8-K under Item 7.01, including t…
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any…
Entry into a Material Definitive Agreement. Registered Public Offering On June 26, 2025, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into agreements, including a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) an aggregate of 20,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Co…
Regulation FD Disclosure. On June 25, 2025, the Company issued a press release regarding the launch of the Offering (the “Launch Press Release”). On June 26, 2025, the Company issued a press release announcing that it had priced the Offering (the “Pricing Press Release”). Copies of the Launch Press Release and the Pricing Press Release are furnished hereto as Exhibits 99.1 and Exhibit 99.2, respectively. The information in this Current Report on Form 8-K under Item 7.01, including the informa…
Changes in Registrant ’ s Certifying Accountant. On June 3, 2025, Reviva Pharmaceutical Holdings Inc., (the "Company") was notified that Moss Adams LLP ("Moss Adams"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025. The combined audit practices will operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the notification of the merger, Moss Adams has resigned as the auditors of the Company effective June 3, 202…
Entry into a Material Definitive Agreement. On May 30, 2025, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Agreement”) with B. Riley Securities, Inc. and Alliance Global Partners, serving as agents (the “Agents”), with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), havi…
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any…
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 13, 2025, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Reviva Pharmaceuticals Holdings, Inc. (the “Company”), approved the compensation arrangements described below with (i) the Company’s named executive officers, consisting of Dr. Laxminarayan Bhat, the Company’s President and Chief Executive O…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.